4//SEC Filing
ROCKLAGE SCOTT M 4
Accession 0001209191-24-002643
CIK 0001516551other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 4:32 PM ET
Size
19.6 KB
Accession
0001209191-24-002643
Insider Transaction Report
Form 4
ROCKLAGE SCOTT M
10% Owner
Transactions
- Purchase
Common Stock
2024-01-31$2.31/sh+5,206,074$12,026,031→ 7,943,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
- 1,718,189(indirect: By 5AM Ventures II, L.P.)
Common Stock
- 67,796(indirect: By 5AM Co-Investors II, L.P.)
Common Stock
DIEKMAN JOHN D
10% Owner
Transactions
- Purchase
Common Stock
2024-01-31$2.31/sh+5,206,074$12,026,031→ 7,943,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
- 67,796(indirect: By 5AM Co-Investors II, L.P.)
Common Stock
- 1,718,189(indirect: By 5AM Ventures II, L.P.)
Common Stock
5AM Partners II, LLC
10% Owner
Transactions
- Purchase
Common Stock
2024-01-31$2.31/sh+5,206,074$12,026,031→ 7,943,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
- 67,796(indirect: By 5AM Co-Investors II, L.P.)
Common Stock
- 1,718,189(indirect: By 5AM Ventures II, L.P.)
Common Stock
PARMAR KUSH
10% Owner
Transactions
- Purchase
Common Stock
2024-01-31$2.31/sh+5,206,074$12,026,031→ 7,943,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
- 67,796(indirect: By 5AM Co-Investors II, L.P.)
Common Stock
- 1,718,189(indirect: By 5AM Ventures II, L.P.)
Common Stock
5AM Partners VII, LLC
10% Owner
Transactions
- Purchase
Common Stock
2024-01-31$2.31/sh+5,206,074$12,026,031→ 7,943,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
- 1,718,189(indirect: By 5AM Ventures II, L.P.)
Common Stock
- 67,796(indirect: By 5AM Co-Investors II, L.P.)
Common Stock
5AM CO-INVESTORS II LP
10% Owner
Transactions
- Purchase
Common Stock
2024-01-31$2.31/sh+5,206,074$12,026,031→ 7,943,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
- 1,718,189(indirect: By 5AM Ventures II, L.P.)
Common Stock
- 67,796(indirect: By 5AM Co-Investors II, L.P.)
Common Stock
5AM Ventures VII, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2024-01-31$2.31/sh+5,206,074$12,026,031→ 7,943,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
- 67,796(indirect: By 5AM Co-Investors II, L.P.)
Common Stock
- 1,718,189(indirect: By 5AM Ventures II, L.P.)
Common Stock
5AM Ventures II LP
10% Owner
Transactions
- Purchase
Common Stock
2024-01-31$2.31/sh+5,206,074$12,026,031→ 7,943,520 total(indirect: By 5AM Ventures VII, L.P.)
Holdings
- 1,718,189(indirect: By 5AM Ventures II, L.P.)
Common Stock
- 67,796(indirect: By 5AM Co-Investors II, L.P.)
Common Stock
Footnotes (3)
- [F1]The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- [F2]The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- [F3]The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
Documents
Issuer
Skye Bioscience, Inc.
CIK 0001516551
Entity typeother
Related Parties
1- filerCIK 0001219014
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 4:32 PM ET
- Size
- 19.6 KB